Decreased striatal dopamine transporter binding assessed with [123I] FP-CIT in first-episode schizophrenic patients with and without short-term antipsychotic-induced parkinsonism
- 214 Downloads
Drug-induced parkinsonism (DIP) is one of the main causes of treatment drop-out in schizophrenic patients causing a high incidence of relapse that leads patients to a bad clinical prognosis. The dopaminergic nigrostriatal pathway is involved in the movement control, so the study of the dopamine transporter (DAT) could be of great value to determine its implication in the appearance of DIP.
The goal of the study is to determine the striatal DAT binding assessed with [123I] FP-CIT SPECT in first-episode neuroleptic-naive schizophrenic in-patients with DIP after short-term antipsychotic treatment.
The [123I] FP-CIT binding ratios of ten schizophrenic in-patients who developed DIP during the first 4-week period of risperidone treatment (6±2 mg/day) were compared with ten schizophrenic in-patients treated with the same doses of risperidone and who do not developed DIP and with ten age-matched healthy subjects. Quantitative analyses of SPECTs were performed using regions of interest located in caudate, putamen and occipital cortex. Parkinsonism was assessed by the Simpson–Angus Scale and the psychopathological status by the Clinical General Impression and Positive and Negative Syndrome Scales.
Whole striatal [123I] FP-CIT binding ratios were significantly lower in patients with and without DIP than in healthy subjects (p<0.001). This was also observed in whole putamen (p<0.001) and caudate nucleus (p<0.001). Females showed higher whole striatal [123I] FP-CIT binding ratios than males (p<0.05). No differences in psychopathological scales were observed between patients with and without DIP.
Our first-episode schizophrenic patients with and without DIP after short-term risperidone treatment have a decreased striatal DAT binding assessed with [123I] FP-CIT. This alteration could be related to the schizophrenic disease or may be secondary to the antipsychotic treatment.
KeywordsSchizophrenia Drug-induced parkinsonism Dopamine transporter [123I] FP-CIT SPECT
Grants from Hospital Clinic of Barcelona (Premi Fi de Residencia 2001), Marató TV3 (Enfermedades Psiquiátricas Graves; 2001), Fondo de Investigación Sanitaria of the Spanish Ministerio de Sanidad y Consumo (contract no. PI020485) and Amersham Health are gratefully acknowledged. Thanks to Mr. J Lara, Ph.D., for his English editorial assistance and Mr. L Jover, Ph.D., for his statistical assistance.
- American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders (4th ed). Washington, USAGoogle Scholar
- Bleuler E (1950) Dementia praecox or the group of schizophrenias. International University Press, New YorkGoogle Scholar
- First MB, Spitzer RL, Williams JBW, Gibbon M (1994) Structured clinical interview for DSM-IV—patients edition (SCID-P). American Psychiatric Press, Washington, DCGoogle Scholar
- Guy W (1976) Early clinical drug evaluation unit (ECDEU), National Institute of Mental Health 76:338. Rockville, USAGoogle Scholar
- Kay SR, Fisbein S, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:262–273Google Scholar
- Kraeplin E (1919) Dementia praecox and paraphrenia. University of Edinburgh, EdinburghGoogle Scholar
- Peralta V, Cuesta M, Campos MS (2002) Sintomas extrapiramidales en pacientes esquizofrénicos nunca tratados con neurolépticos. Aula Méd Psiquiátr 4:269–280Google Scholar
- Rajput AH, Rozdilsky B, Hornykiewicz O, Shannak K, Lee T, Seeman P (1982) Reversible drug-induced parkinsonism. Clinicopathologic study of two cases. Arch Neurol 10:644–646Google Scholar
- Tatsch K, Scherer J, Linke R, Kerner M, Hahn K (1999) Decrease of dopamine transporter binding in neuroleptic-free schizophrenic patients assessed with IPT-SPECT (abstr.) J Nucl Med 40:31Google Scholar